The Journal of Immunology, Vol 156, Issue 11 4401-4407, Copyright © 1996 by American Association of Immunologists

ARTICLES

Release of leukemia inhibitory factor in primate sepsis. Analysis of the role of TNF-alpha

PM Jansen, IW de Jong, M Hart, KJ Kim, LA Aarden, LB Hinshaw, FB Taylor Jr and CE Hack
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Clinical and Experimental Immunology, University of Amsterdam, The Netherlands.

Leukemia inhibitory factor (LIF), a pleiotropic cytokine with many biologic effects overlapping with those of IL-6, has been implicated in the pathogenesis of sepsis. We here analyzed the kinetics of LIF in 13 baboons challenged with a lethal (n=6) or sublethal (n=7) dose of Escherichia coli. In addition, to assess the role of TNF-alpha in the induction of LIF in vivo, seven baboons were studied that had either received a bolus injection of recombinant human TNF-alpha (100 micrograms/kg, n=3), or to whom 15 mg/kg of an anti-TNF mAB before lethal E. coli challenge was administered (n=4). LIF levels increased 2 h after E coli challenge, and reached maximum values at 4 and 8 h after a sublethal (4.4 +/- 1.6 ng/ml) or lethal (40.9 +/- 3.8 ng/ml) dose, respectively. TNF-alpha injection induced a modest rise in LIF concentrations, peaking after 6 h (228 +/- 46 pg/ml). Circulating LIF correlated with plasma levels of IL-6, both after E. coli challenge (Spearman Rank coefficient of correlation (r) = 0.849, p<0.001), as well as upon TNF-alpha injection (r=0.863, p<0.001). Moreover, the E. coli-induced release of either cytokine was reduced 6- to 10-fold after pretreatment with anti-TNF mAb, except in one nonsurviving animal, which exhibited a progressive increase of LIF and IL-6 levels despite the absence of TNF immunoreactivity. These results show that TNF-alpha is an intermediate factor in concerted release of LIF and IL-6 in vivo, and indicate that the enhanced elaboration of these cytokines may predict disease outcome in severe sepsis.

This article has been cited by other articles:

				W. Pan, C. Yu, H. Hsuchou, Y. Zhang, and A. J. Kastin Neuroinflammation facilitates LIF entry into brain: role of TNF Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1436 - C1442. [Abstract] [Full Text] [PDF]

				M. A. Lindorfer, A. Nardin, P. L. Foley, M. D. Solga, A. J. Bankovich, E. N. Martin, A. L. Henderson, C. W. Price, E. Gyimesi, C. P. Wozencraft, et al. Targeting of Pseudomonas aeruginosa in the Bloodstream with Bispecific Monoclonal Antibodies J. Immunol., August 15, 2001; 167(4): 2240 - 2249. [Abstract] [Full Text] [PDF]

				C. J. Auernhammer and S. Melmed Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function Endocr. Rev., June 1, 2000; 21(3): 313 - 345. [Abstract] [Full Text]

				B. P. Haines, R. B. Voyle, T. A. Pelton, R. Forrest, and P. D. Rathjen Complex Conserved Organization of the Mammalian Leukemia Inhibitory Factor Gene: Regulated Expression of Intracellular and Extracellular Cytokines J. Immunol., April 15, 1999; 162(8): 4637 - 4646. [Abstract] [Full Text] [PDF]

				D. A. Knight, C. P. Lydell, D. Zhou, T. D. Weir, R. Robert Schellenberg, and T. R. Bai Leukemia Inhibitory Factor (LIF) and LIF Receptor in Human Lung . Distribution and Regulation of LIF Release Am. J. Respir. Cell Mol. Biol., April 1, 1999; 20(4): 834 - 841. [Abstract] [Full Text]

				P. M. Jansen, B. Eisele, I. W. de Jong, A. Chang, U. Delvos, F. B. Taylor Jr., and C. E. Hack Effect of C1 Inhibitor on Inflammatory and Physiologic Response Patterns in Primates Suffering from Lethal Septic Shock J. Immunol., January 1, 1998; 160(1): 475 - 484. [Abstract] [Full Text] [PDF]